CALA Calithera Biosciences Inc.

6.75
-0.15  -2%
Previous Close 6.9
Open 6.94
Price To Book 3.01
Market Cap 428,625,000
Shares 63,500,000
Volume 526,319
Short Ratio
Av. Daily Volume 666,312
Stock charts supplied by TradingView

NewsSee all news

  1. Calithera Biosciences Provides Overview of 2020 Corporate Milestones and Financial Guidance

    SOUTH SAN FRANCISCO, Calif., Jan. 13, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (NASDAQ:CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the

  2. Calithera Biosciences Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    SOUTH SAN FRANCISCO, Calif., Jan. 03, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (NASDAQ:CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the

  3. Data from Investigator-Sponsored Phase 2 Study of Calithera's Telaglenastat with Azacitidine in Myelodysplastic Syndrome to be Presented at ASH Annual Meeting 2019

    SOUTH SAN FRANCISCO, Calif., Dec. 06, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (NASDAQ:CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the

  4. Calithera Biosciences Announces New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    SOUTH SAN FRANCISCO, Calif., Dec. 05, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (NASDAQ:CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the

  5. Calithera Biosciences Reports Third Quarter 2019 Financial Results and Recent Highlights

    SOUTH SAN FRANCISCO, Calif., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (NASDAQ:CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 trial ongoing but will not pursue development.
CB-839 with paclitaxel
Triple negative breast cancer
Phase 2 data at ESMO 2019 noted HR 0.64. PFS 3.8 months.
CB-839 + AFINITOR (everolimus)‎ - ENTRATA
Clear cell renal cell carcinoma
Phase 1/2 enrollment commenced August 2016. Oral presentation November 11, 2017 at 32nd Annual Meeting of the Society for Immunotherapy of Cancer (SITC).
CB-839 + nivolumab
Renal cell carcinoma, malignant melanoma and non-small cell lung cancer
Phase 2 top-line data due 2H 2020.
CB-839 + Cabozantinib (CANTATA)
Renal cell carcinoma
Phase 2 portion of trial is ongoing.
CB-839 + Panitumumab
Colorectal cancer
Phase 1 poster at ASCO June 4, 2018 8am.
CB-839 + Capecitabine
Solid tumors
Phase 1 presentation at ASCO June 2018. PFS 26 weeks.
CB-839 plus capecitabine
Solid tumors
Phase 1/2 trial initiation announced March 26, 2019.
CB-839 plus talazoparib
Triple negative breast cancer
Phase 1/2 data at ESMO 2019 noted - 7% PR rate.
INCB001158
Solid tumors
Phase 1b trial to be initiated 1H 2020.
CB-280
Cystic fibrosis
Phase 1/2 initiation announced July 2, 2019.
Telaglenastat (CB-839) + palbociclib
KRAS-mutated colorectal cancer (CRC) and KRAS-mutated non-small cell lung cancer (NSCLC)
Phase 2 data presented at ASH December 2019.
Telaglenastat (CB-839) and azacitidine
Myelodysplastic Syndrome

Latest News

  1. Calithera Biosciences Provides Overview of 2020 Corporate Milestones and Financial Guidance

    SOUTH SAN FRANCISCO, Calif., Jan. 13, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (NASDAQ:CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the

  2. Calithera Biosciences Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    SOUTH SAN FRANCISCO, Calif., Jan. 03, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (NASDAQ:CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the

  3. Data from Investigator-Sponsored Phase 2 Study of Calithera's Telaglenastat with Azacitidine in Myelodysplastic Syndrome to be Presented at ASH Annual Meeting 2019

    SOUTH SAN FRANCISCO, Calif., Dec. 06, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (NASDAQ:CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the

  4. Calithera Biosciences Announces New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    SOUTH SAN FRANCISCO, Calif., Dec. 05, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (NASDAQ:CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the

  5. Calithera Biosciences Reports Third Quarter 2019 Financial Results and Recent Highlights

    SOUTH SAN FRANCISCO, Calif., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (NASDAQ:CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the

  6. Calithera to Present Preclinical Data from IL4I1 and CD73 Programs at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

    - First presentation of preclinical data for newly-announced IL4I1 immuno-oncology program - Additional data demonstrate potential of CD73 inhibitor CB-708 to combine with immuno-oncology and chemotherapy agents in

  7. Calithera Biosciences to Report Third Quarter 2019 Financial Results on Tuesday, November 12, 2019

    SOUTH SAN FRANCISCO, Calif., Nov. 04, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (NASDAQ:CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the

  8. Calithera Biosciences Completes Patient Enrollment in Randomized CANTATA Trial of Telaglenastat and Cabozantinib in Advanced Renal Cell Carcinoma

    -Top-line results expected in second half of 2020- SOUTH SAN FRANCISCO, Calif., Oct. 03, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (NASDAQ:CALA), a clinical stage biotechnology company focused on

  9. Calithera Announces Acceptance of Two Abstracts for Presentation at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting

    First preclinical data for newly-announced IL4I1 immuno-oncology programPreclinical data for orally bioavailable CD73 inhibitor CB-708 SOUTH SAN FRANCISCO, Calif., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Calithera

  10. New Data Presented at ESMO Congress 2019 from the Arginase Inhibitor INCB001158 Alone and in Combination with Pembrolizumab

    SOUTH SAN FRANCISCO, Calif., Sept. 29, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (NASDAQ:CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the

  11. Data From Randomized Phase 2 ENTRATA Study Demonstrate Telaglenastat with Everolimus Improves Progression-Free Survival in Renal Cell Carcinoma

    Data shared today in oral presentation at ESMO Congress 2019 show telaglenastat doubles median progression-free survival (PFS) in heavily pre-treated patients with advanced disease, reduced risk of death by 36% (HR=0.64,

  12. Calithera to Host Webcast Conference Call for Analysts and Investors During European Society for Medical Oncology (ESMO) Congress 2019

    SOUTH SAN FRANCISCO, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (NASDAQ:CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the

  13. Calithera to Present at the 2019 Cantor Global Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., Sept. 25, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (NASDAQ:CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the

  14. Calithera Biosciences to Present New Data on Two Oncology Programs at ESMO Congress 2019

    -Results from ENTRATA Phase 2 trial of telaglenastat in patients with advanced renal cell carcinoma (RCC) accepted as Late Breaking Oral Presentation- -Data from INCB001158 clinical program accepted as Oral

  15. Calithera to Participate in Wells Fargo Healthcare Conference and Citi 14th Annual Biotech Conference

    SOUTH SAN FRANCISCO, Calif., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (NASDAQ:CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the